CompanyChiome Bioscience Inc.
Japan
Chiome Bioscience, is a public company leveraging the ADLib® System, a proprietary monoclonal antibody generating technology, for drug discocery and development, as well as providing drug discovery supports.
Private/Public:
public
Phone:+81-3-6383-3561
Fax:+81-3-5302-1311
Website:https://www.chiome.co.jp/?id=en
Address:Sumitomo-Fudosan Nishi-shinjuku bldg. No.6, 3-12-1 Honmachi, Shibuya-ku, Tokyo 151-0071, Japan
2005
Since
1
Country
4
Top Service Categories
16
Sub-Service Categories
API/Biologicals Production
API/Biologics development and manufacturing
Discovery and Preclinical
Chemistry/Discovery Tech./In silico services
| Facility Type | Address | Telephone | City | Fax | Country | State Code | Service Categories | Facility Size | Year Built | Number Of Employees | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Corporate Headquarters,R&D/Innovation Centers | Sumitomo-Fudosan Nishi-shinjuku bldg. No.6, 3-12-1 Honmachi, Shibuya-ku, Tokyo 151-0071 | +81-3-6383-3561 | Tokyo | +81-3-5302-1311 | Japan | ||||||
| R&D/Innovation Centers | Teikyo University Biotechnology Research Center 1F 2-13-3 Nogawahonmachi, Miyamae-ku, Kawasaki-city, Kanagawa 216-0041 | +81 - 44 -766 -2119 | Kawasaki | Japan |
- (13.Jun.2022) Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study
- (13.May.2022) Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31, 2022
- (21.Apr.2022) Announcement of Launch of a Diagnostic Kit by Fujirebio Inc
- (16.Feb.2022) Submission of the Application for a Phase I Study of CBA-1535
- (15.Feb.2022) License Agreement for a Diagnostic Kit with Fujirebio, Inc
- (14.Feb.2022) Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021
- (24.Dec.2021) Move to the Second Half Part of Phase 1 Clinical Trial of First-In-Class CBA-1205
- (18.Oct.2021) Extension of Contract with Chugai